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This study aimed to compare the inhibitory effects of photosensitizers loaded in hollow silica nanoparticles and
conventional photosensitizers on HepG2 human hepatoma cell proliferation and determine the underlying
mechanisms. Photosensitizers (conventional Photosan-II or nanoscale Photosan-II) were administered to in vitro
cultured HepG2 hepatoma cells and treated by photodynamic therapy (PDT) with various levels of light exposure.
To assess photosensitizers' effects, cell viability was determined by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. In addition, apoptotic and necrotic cells were measured by flow cytometry and the expression of
caspase-3 and caspase-9 evaluated by western blot. Finally, the in vivo effects of nanoscale and conventional
photosensitizers on liver cancer were assessed in nude mice. Nanoscale Photosan-II significantly inhibited hepatoma
cell viability in a concentration-dependent manner and this effect was more pronounced with high laser doses. Moreover,
nanoscale photosensitizers performed better than the conventional ones under the same experimental conditions
(p < 0.05). Flow cytometry data demonstrated that laser-induced cell death was markedly increased after treatment
with nanoscale Photosan-II in comparison with free Photosan-II (p < 0.05). Activated caspase-3 and caspase-9 levels
were significantly higher in cells treated with Photosan-II loaded in silica nanoparticles than free Photosan-II
(p < 0.05). Accordingly, treatment with nanoscale photosensitizers resulted in improved outcomes (tumor volume)
in a mouse model of liver cancer, in comparison with conventional photosensitizers. Hollow silica nanoparticles
containing photosensitizer more efficiently inhibited hepatoma cells than photosensitizer alone, through induction
of apoptosis, both in vivo and in vitro.
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Primary liver cancer is one of the top malignancies
around the world with respect to morbidity and mortality
[1]. Liver cancer cases reported in China account for
43.7% of people affected by this disease in the world. Still
in China, liver cancer is the second most fatal malignancy,
accounting for 20.37 deaths per 100,000 individuals [2].
Moreover, liver cancer incidence has steadily increased
in recent years and constitutes a serious threat to health
in China. The onset of primary liver cancer is relatively* Correspondence: 4896142@qq.com; 13787782059@163.com
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in any medium, provided the original work is pasymptomatic, rendering early diagnosis very difficult.
In addition, this cancer is difficult to treat because it
typically develops from liver cirrhosis and high rates of
liver cancer recurrence and metastasis occur even after
clinical diagnosis and treatment. Due to various issues,
such as lack of specific treatments, limited innovative
medications, and dearth of therapeutic options, it is par-
ticularly important and urgent to develop new tech-
niques and therapies for diagnosis and treatment of
liver cancer [3].
Photodynamic therapy (PDT), a new method developed
during the past 2 decades for the treatment of malignant
tumors, has shown good therapeutic effects on a variety ofpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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been conducted to test whether this therapy can be used
for hepatic and other intraperitoneal tumors. PDT in-
volves two processes: (1) light sensitivity is achieved by
the administration of photosensitizers to patients and (2)
light is transmitted through an optical fiber to the region
of the body containing the tumor. Irradiation with light of
appropriate wavelength will activate the photosensitizer,
which transfers energy to oxygen, triggering a series of re-
actions leading to cell apoptosis or necrosis. Therefore,
photosensitizers play a key role in PDT. Conventional
PDT efficacy is restricted by insufficient selectivity, low
solubility of photosensitizers, and limited penetration
depth of the 630-nm laser light, which reduces the PDT
efficacy for tumors located in deeper tissues compared
with those at the body surface. In order to improve the
photodynamic efficacy, a photosensitizer with high perme-
ability and low side effects must be provided [6,7], which
allows concentrations to reach the required level for PDT.
Recent progress in nanopharmaceutical research has pro-
posed a few methods to tackle these problems [8]. Re-
searchers have developed various types of nanoscale drug
carriers to deliver photosensitizers, such as liposomes
[4,5], polymer carriers [9], polyoxyethylene cremophor
emulsions [10], and microspheres and nanoparticles [11].
Although these carriers improve photosensitizer proper-
ties, their use necessarily involves processes to release the
loaded drugs that decrease the rate at which tumor cells
absorb photosensitizers, extending the period of time re-
quired to reach effective concentrations [12]. Therefore,
the development of nanocarriers that do not require an
extensive process for releasing loaded photosensitizers
would greatly enhance photosensitizer effectiveness by
shortening this time period. Because nanoparticles are
ideal carriers of photosensitizers [13], the use of silica
nanoparticles as carriers for photosensitizers is an ex-
tremely viable option [14].
In this study, we aimed to compare the inhibitory effects
of photosensitizers loaded in hollow silica nanoparticles
and conventional photosensitizers on HepG2 human
hepatoma cell proliferation and determine the underlying
mechanisms in vitro. We found that nanoscale photosen-
sitizers were more efficient in HepG2 cell inhibition com-
pared with conventional photosensitizers. In addition,
levels of activated caspase-3 and caspase-9 were signifi-
cantly higher in cells treated with Photosan-II loaded in
nanoparticles than free Photosan-II. Finally, treatment
with nanoscale photosensitizers increased mouse survival
and reduced tumor volume in mice to a greater extent
compared with free photosensitizers.
Overall, our data indicate that hollow nanoparticles
containing photosensitizers more efficiently inhibit hepa-
toma cells than free photosensitizers, through induction
of apoptosis, both in vivo and in vitro.Methods
Cell lines
The HepG2 human hepatoma cell line was purchased
from the cell center of the Xiangya School of Medicine
of Central South University.
Experimental animals
Specific pathogen-free (SPF)-grade female BALB/c nude
mice (26 to 30 days, 18 to 22 g) were obtained from the
Shanghai Laboratory Animal Center of the Chinese
Academy of Sciences. Mice were housed in SPF-grade
animal laboratory of the Second Xiangya Hospital of
Central South University in a temperature and humidity
controlled room with food and water ad libitum. All
procedures were approved by the Animal Ethical
Committee of Second Xiangya Hospital of Central
South University.
Preparation of nanoscale photosensitizers
Nanoscale photosensitizers were prepared using a one-
step wet chemical-based synthesis at room temperature, as
previously described [15]. Tetraethyl orthosilicate (TEOS,
99.99%), polyacrylic acid (PAA, M.W= 3,000) were pur-
chased from Aladdin Chemistry Co. Ltd (Shanghai, China).
Anhydrous ethanol (99.7%) and ammonia (25% to 28%)
were purchased from Sinopharm Chemical Reagent Co.
Ltd (China) and Photosan-II (C34H38N4NaO5) obtained
from Seehof Laboratorium F&E GmbH (Wesselburenerkoog,
Germany). The resulted nanoscale photosensitizers (Photo-
san-II-loaded hollow silica nanospheres, 10 mg/L) showed
good sphericity and narrow diameter distribution, ranging
from 25 to 90 nm (mean value 37.8 nm). The encapsula-
tion efficiency reached 95%.
Cell culture and passaging
Cryopreserved HepG2 human hepatoma cells were thawed
and cultured in appropriate volume of 10% fetal bovine
serum (FBS) in Dulbecco's modified Eagle's medium
(DMEM) purchased from Gibco (USA), at 37°C and 5%
CO2. Cell growth was observed daily, and culture media
were changed as needed. Cells grown to logarithmic phase
were trypsinized and passaged.
MTT assay
Two hundred microliters of a 105 cells/mL suspension
was seeded into a 96-well plate and cultured as described
above. Photosensitizers used were either conventional
Photosan or nanoscale Photosan. The following groups
were set: (1) blank control, no photosensitizer and no
light; (2) photosensitizer-only group, different concentra-
tions of photosensitizers but not light; (3) light-only group,
no photosensitizer treatment, exposure to light of different
intensities; (4) experimental groups, with cells treated with
different concentrations of photosensitizers and exposed
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mental groups were cultured in the presence of 0, 1.25,
2.5, 5, 10, or 20 mg/L photosensitizer for 1, 2, and 4 h
followed by exposure to light at 2.5, 5, or 10 J/cm2 and
culture for an additional 24 h. Cell inhibition rates were
determined after treatment with 3-(4, 5-dimethylthiazol-2-yl)-
2,5-diphenyltet-razolium bromide (MTT) obtained from
Sigma-Aldrich (St. Louis, MO, USA) as previously de-
scribed [16]. Each experiment was repeated three times.Flow cytometry experiments
Based on the results obtained in MTT assays, four groups
shown in Table 1 were analyzed by flow cytometry: Cells
were stained using the Annexin-V-FLUOS staining kit
purchased from Roche (Nutley, NJ, USA), following the
manufacturer's instructions. Briefly, 105 resuspended cells
were gently resuspended in 195 μL of Annexin V-FITC
binding buffer followed by the addition of 5 μL of Annexin
V-FITC and incubation in the dark at room temperature
(20°C 25°C) for 10 min. After washing, cells were incu-
bated in binding buffer containing propidium iodide (PI).
Annexin V-FITC produced green fluorescence while PI
produced red fluorescence. These experiments were re-
peated three times.Evaluation of caspase-3 and caspase-9 levels by western
blot
Three groups of cells were analyzed: a normal control
group (A), a nanoscale photosensitizer group (B), and a
conventional photosensitizer group (C). Cells in groups
B and C were treated with 5 mg/L photosensitizer and
irradiated at 5 J/cm2 for 2 h. After treatment, cells were
lysed in 500 μL radioimmunoprecipitation assay (RIPA)
lysis buffer on ice for 30 min. After centrifugation at
12,000 rpm for 5 min at 4°C, protein concentrations
were determined in supernatants using the BCA Protein
Assay Kit (Wellbio, China) according to the manufactur-
er's instructions. Equal amounts of proteins were sepa-
rated by electrophoresis on a precast 15% polyacrylamide
gel and transferred onto polyvinylidene difluoride (PVDF)
membranes. After blocking, the membranes were incu-
bated overnight at 4 °C with rabbit anti-human caspase-3/
caspase-9 monoclonal antibodies purchased from Boster
Biological Engineering Co. (Wuhan, China). After wash-
ing, membranes were incubated in horseradish peroxid-
ase (HRP)-labeled secondary antibodies (1:3,000) for 45
to 60 min and detected with an enhanced chemiluminescenceTable 1 Four groups with various processing methods
Group A B C
Processing methods Blank control PDT treatment and nanoscale




f(ECL) chromogenic substrate. Images were obtained by
autoradiography and scanned for analysis.
In vivo tumor inhibition in a mouse model of liver cancer
Routinely cultured hepatoma cells were collected,
washed with PBS, and resuspended in PBS to 2 × 106
cells/mL. A total of 0.2 mL of the prepared cell suspen-
sion (4 × 105 HepG2 cells) was injected into the right
armpit of each nude mouse and tumor growth observed
every other day. Typically, subcutaneous foreleg tumors
became visible after 5 to 7 days. At this time, tumor
sizes were measured with Vernier calipers, and the long
diameter, short diameter, and height of each tumor were
recorded. Treatment started when tumor volumes
reached approximately 0.5 cm3. The mice were ran-
domly divided into the following groups (n = 15): normal
control animals (neither photosensitizer nor light treat-
ment), and nanoscale photosensitizer and conventional
photosensitizer treatment groups. Each animal in the
treatment groups received an intraperitoneal injection of
10 mg photosensitizer per kilogram. Four hours later,
animals were irradiated with a 63-nm laser (500 mW,
10 min). The subcutaneous xenograft tumors were el-
lipsoid in shape; thus, tumor volumes were calculated
using the equation for ellipsoid volume: V = a × b × c ×
π × 4/3 (a: long diameter of the tumor; b: short diameter
of the tumor; c: tumor height). After treatment, tumor
sizes were measured every other day with Vernier cali-
pers. Tumor dimensions were determined by averaging
three repeated measurements. Lag phases in tumor
growth before and after treatment and final mouse sur-
vival times were recorded.
Statistical analyses
Statistical analyses were performed using the SPSS stat-
istical software version 12.0 (SPSS Inc., Chicago, IL,
USA). All data were expressed as mean ± SD. Compari-
son of multiple independent samples were performed by
one-way analysis of variance (ANOVA) and p < 0.05 con-
sidered statistically significant.
Discussion
Cytotoxic effects of conventional and nanoscale
photosensitizer PDT on human hepatoma cells
At fixed photosensitizer concentrations and laser irradiation
doses, cell viability was significantly affected by the incuba-
tion time. In addition, cell viability was significantly lower
in cells subjected to nanoscale photosensitizer-mediatedD
DT treatment with conventional
hotosan, using optimal parameters
or nanoscale Photosan
PDT treatment with conventional
Photosan, using optimal parameters
for conventional Photosan
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tizers. In HepG2 cells treated with 5 mg/L conventional
Photosan and irradiated at 10 J/cm2, viability declined
from 0 to 4 h and remained stable thereafter. In the nano-
scale Photosan group, significant differences in cell viabil-
ity were observed after 1 and 2 h of incubation, whereas
cells treated for more than 2 h exhibited no significant dif-
ferences in cell viability (Figure 1A). According to these
data, 4 and 2 h were used in subsequent experiments for
conventional and nanoscale photosensitizers, respectively.
At fixed incubation times and laser irradiation doses,
cell viability significantly differed with photosensitizer
concentrations. In addition, cell viability was significantlyFigure 1 The impacts of (A) incubation times, (B) Photosan
concentrations, and (C) light dose on cytotoxic effects of PDT.
(B) Conventional Photosan and nanoscale Photosan concentrations
on cytotoxic effects of PDT. *Significant difference (P < 0.05) of cell
viability was detected between two groups at the time point.lower in cells subjected to nanoscale photosensitizer-
mediated PDTs than in cells treated with the conven-
tional. In the conventional Photosan group, cells incu-
bated for 2 h at 10 J/cm2 cell showed a gradual decline
in viability as Photosan concentrations increased from 0
to 20 mg/L, with significant differences in cell viabilities
at different concentrations. At 20 mg/L, no statistically
significant differences in cell viability were observed be-
tween conventional and nanoscale Photosan treatments.
HepG2 cell-treated nanoscale Photosan showed a different
pattern: cell viability declined as photosensitizer concen-
trations increased from 0 to 5 mg/L and stabilize there-
after (Figure 1B). According to these findings, 10 and
5 mg/L were used in subsequent experiments for conven-
tional and nanoscale photosensitizers, respectively.
At fixed photosensitizer incubation times and concen-
trations, cell viability was significantly affected by light
doses. In addition, cell viability was significantly lower in
cells subjected to nanoscale photosensitizer-mediated
PDTs than in cells treated with the conventional. In the
conventional Photosan group, cells incubated for 2 h in
the presence of 5 mg/L photosensitizer showed a gradual
decline in cell viability as light doses increased from 2.5
to 10 J/cm2, with significant differences at different light
doses. In cells treated with nanoscale Photosan, signifi-
cant differences in cell viability were observed between
exposure at different light intensities, from 0 to 5 J/cm2,
with no significant difference in cell viability observed
thereafter (Figure 1C). Accordingly, 10 and 5 J/cm2 were
used in further experiments for conventional and nano-
scale photosensitizers, respectively.
Effects of conventional and nanoscale photosensitizers
PDT on human hepatoma cell apoptosis
Flow cytometry was used to quantitate apoptosis rates
in human hepatoma cells submitted to conventional
Photosan-based PDT or nanoscale Photosan-based PDT.
Group a cells were the blank control; group b cells were
treated with 5 mg/L nanoscale Photosan for 2 h at 5
J/cm2; group c cells received 5 mg/L conventional
Photosan for 2 h at 5 J/cm2; group d cells were treated
with 10 mg/L conventional Photosan for 4 h at 10 J/cm2.
As shown in Figure 2, apoptosis rates for groups a, b, c,
and d were 17.14%, 80.33%, 40.66%, and 72.33%, respect-
ively. The treatment groups (groups b, c, and d) signifi-
cantly differed from the control group a (P < 0.05). Total
apoptosis rates were similar in groups b and d (P > 0.05),
and significantly higher in group b compared with group c
(P < 0.05). Flow cytometry data further confirmed the
cytotoxic effects of PDT as detailed above. Under the
same experimental conditions, the cytotoxic effects of
conventional Photosan-mediated PDT were significantly
lower than those of nanoscale Photosan-mediated PDT
(P < 0.05). In addition, a comparison of conventional
Figure 2 Flow cytometry analyses of groups A, B, C, and D. Group A cells are the blank control; group B cells were treated with 5 mg/L
nanoscale Photosan for 2 h at 5 J/cm2; group C, cells received 5 mg/L conventional Photosan for 2 h at 5 J/cm2; group D cells were treated with
10 mg/L conventional Photosan for 4 h at 10 J/cm2. Lower left quadrants represent normal cells; lower right quadrants are early apoptotic cells;
upper right quadrants represent late, dead apoptotic cells; upper left quadrants are mechanically damaged cells. The apoptotic rate was defined
as100* (sum of early apoptotic and late apoptotic cells)/total number of cells.
Figure 3 Active caspase-3 (A) and caspase-9 (B) protein levels in
cancer cells after conventional and nanoscale photosensitizer
PDT. A1, A2, and A3: blank control samples; B1, B2, and B3: nanoscale
Photosan-treated samples; C1 and C2: Photosan-treated samples.
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respective optimal parameters indicated the superiority
of nanoscale Photosan in inhibiting cancer cell growth
(P < 0.05) as shown in Figure 2.
Caspase-3 and caspase-9 protein levels in hepatoma cells
submitted to conventional and nanoscale photosensitizer
PDT
Western blot data demonstrated that PDT with 5 mg/L
photosensitizer for 3 h at 5 J/cm2 resulted in higher level
of active form of caspase-3 (20 kD) in both nanoscale
Photosan and conventional Photosan-treated samples
(Figure 3A). Interestingly, caspase-3 levels were signifi-
cantly higher in nanoscale photosensitizer-treated cells
compared with cells treated with conventional photosen-
sitizers (P < 0.05). Similar results were obtained for active
caspase-9 (Figure 3B).
Therapeutic effects of conventional photosensitizers and
nanoscale photosensitizer PDT on human hepatoma
xenografts in nude mice
Table 2 shows the subcutaneous xenograft tumor vol-
umes (cm3) in nude mice after various treatments during
14 days. Prior to PDT, no significant differences in
tumor volume were observed among groups and before
treatment, tumor growth was relatively fast, with tumorsreaching 0.5 ± 0.03 cm3 2 weeks after cancer cell injec-
tion. In the nanoscale photosensitizer group, significant
necrosis in tumor tissues was observed 1 to 2 days after
PDT: tumor volumes started to rapidly decrease, and tis-
sue regeneration caused the formation of scabs at the
wound surface. After 6 to 8 days, the scab wound surface
had been shed, and tumor regrowth was observed.
Table 2 Subcutaneous xenograft tumor volumes (cm3) in nude mice
Group A Group B Group C P(A/B) P(A/C) P(B/C)
1. 15 15 15 - - -
2. 0.525 ± 0.019 0.520 ± 0.013 0.527 ± 0.015 0.588 0.876 0.487
3. 0.867 ± 0.031 0.250 ± 0.010* 0.412 ± 0.013* 0.000 0.000 0.856
4. 1.236 ± 0.039 0.112 ± 0.013* 0.217 ± 0.011* 0.000 0.000 0.770
5. 1.750 ± 0.169 0.035 ± 0.014*# 0.105 ± 0.038* 0.000 0.000 0.020
6. 2.251 ± 0.162 0.114 ± 0.020*# 0.406 ± 0.050* 0.000 0.000 0.001
7. 2.451 ± 0.397 0.266 ± 0.042*# 0.608 ± 0.076* 0.000 0.000 0.008
8. 2.657 ± 0.411 0.475 ± 0.058*# 1.058 ± 0.170* 0.000 0.000 0.004
9. 3.050 ± 0.438 0.623 ± 0.108*# 1.551 ± 0.180* 0.000 0.000 0.000
1. Number of animals; 2. Before treatment; 3. 2 days after treatment; 4. 4 days after treatment; 5. 6 days after treatment; 6. 8 days after treatment; 7. 10 days after
treatment; 8. 12 days after treatment; 9. 14 days after treatment; Group A - blank control; Group B - nanoscale Photosan group; Group C - conventional Photosan
group; P(A/B) - P value for comparing group A and group B; P(A/C) - P value for comparing group A and group C; P(B/C) - P value for comparing group B and
group C. *Significantly different (P < 0.05) from group A, #Significantly different (P < 0.05) from group C.
Figure 4 Tumor volumes after treatments during 14 days (A)
and their digital photographs (B). (A) When tumor volumes
reached approximately 0.5 cm3, one group of the mice did not
receive any treatment (A, Control group) and two groups of the
mice received treatment with conventional Photosan (C, Free PS
group) and nanoscale photosensitizer (B, PS-load HSNP group),
respectively. The tumor sizes were measured in the following 14 days.
Significantly different (P < 0.05) from group A, #Significantly different
(P < 0.05) from group C. The digital photograph of the tumor volumes
of the three groups before treatment (B) and 14 days after treatment
(C). Where, A is the control group; B is PS-load HSNP group and C is
the Free PS group.
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slower in this group compared with control mice and ani-
mals treated with conventional Photosan. In conventional
Photosan PDT group, the therapeutic effects observed
during early stages after PDT treatment were similar to
those in the nanoscale Photosan group. However, after the
necrotic tissue shedding, scabs formed at wound surfaces
and tumors regenerated quickly. Of note, tumor volumes
in nanoscale and conventional Photosan groups were
significantly smaller than sthose obtained for control
animals from 2 days post-treatment throughout the ex-
periment (P < 0.05). Tumor volumes were similar in nano-
scale and conventional Photosan groups 6 days after
treatment; however, after this time point, tumor were sig-
nificantly smaller in the former group compared with the
latter (p < 0.05) , as shown in Figure 4A and the digital
photograph before treatment (Figure 4B) and 14 days after
treatment 4c.
Primary liver cancer (hepatocellular carcinoma) is the
most common type of malignant tumor in China. Al-
though surgical excision and liver transplantation ther-
apies can significantly prolong the survival of liver
cancer patients, most patients are only diagnosed at
later stages and cannot be surgically treated. Therefore,
non-surgical approaches play a vital role in the treat-
ment of primary liver cancer; however, non-surgical ap-
proaches have generally exhibited extremely limited
therapeutic efficacy [17].
PDT is a novel tumor treatment approach developed
since the 1980s. The basic principle of PDT is that pho-
tosensitizers can be selectively taken up and retained in
tumor tissues; thus, the excitation of these photosensi-
tizers by exposure to specific wavelengths of light can
generate cytotoxic singlet oxygen atoms and/or oxygen-free
radicals that achieve the therapeutic objectives of killing
tumor cells, disrupting tumor blood vessels, stimulating
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crosis and shedding among tumor cells [18].
PDT involves lasers and photosensitive drugs (photo-
sensitizers). In particular, the photosensitizers (or their
metabolites) under excitation at appropriate wavelengths
of light produce photodynamic effects, which can des-
troy the targeted cells. The introduction, development,
and application of PDT have been accompanied by grad-
ual improvement of photosensitizers. However, most
photosensitizers discussed in available reports exhibit
certain shortcomings mainly related to hydrophobicity
or limited solubility in aqueous solutions. This issue
causes various deleterious effects that impair the thera-
peutic value of these photosensitizers, including accu-
mulation in bodily fluids (such as blood), alteration of
photosensitizer photochemical properties, and reduction
of singlet oxygen production. Recent progress in nano-
pharmaceutical research has proposed a few methods to
tackle these problems [8]. Silica nanoparticles have drawn
increasing attention due to several advantages, including
extremely controllable shape and size, good water solubil-
ity, stability, and high biocompatibility. More importantly,
silica nanoparticles are permeable to small molecules such
as singlet oxygen [19,20], the key impact factor in PDT,
and the small size of these nanoparticles allows them to
permeate through cell membranes [21,22]. Therefore, the
use of silica nanoparticles provides clear advantages to
overcome conventional nanocarriers that require photo-
sensitizer release processes to occur [23]. Therefore, silica
nanoparticles constitute an ideal nanocarrier that can en-
hance the photodynamic effects of photosensitizers, as
shown elsewhere [15].
In in vitro experiments, we first used MTT assays to
confirm that both conventional Photosan- and nanoscale
Photosan-mediated PDT resulted in HepG2 hepatoma
cell cytotoxicity. We found that relative to conventional
Photosan, nanoscale Photosan was more cytotoxic, re-
quired shorter photosensitizer incubation times, and en-
hanced PDT efficacy. In addition, experiments revealed
that nanoscale photosensitizers did not exhibit cytotox-
icity. These findings provide a basis for promoting the
use of photosensitizers. These findings regarding the
relatively higher cytotoxic effects of nanoscale Photosan-
mediated PDT were further confirmed by flow cytome-
try. Under the same experimental parameters, treatment
with nanoscale Photosan resulted in significantly im-
proved therapeutic effects than conventional Photosan
treatments. Indeed, the use of conventional Photosan at
higher concentrations and longer incubation still pro-
duced cell death rates significantly lower than that ob-
served in the nanoscale Photosan groups. In addition,
we demonstrated that apoptosis is involved in cell death
triggered by conventional Photosan and nanoscale Photosan.
Interestingly, nanoscale Photosan-mediated PDT produceda higher proportion of apoptotic cells than conventional
Photosan.
Furthermore, in in vivo experiments using a mouse
model liver cancer, changes in tumor volume, tumor
growth, and mean mouse survival times in response to
treatment were assessed, after treatment with the two
photosensitizer types. Our results clearly indicated that
significantly better therapeutic efficacy was obtained
with nanoscale photosensitizers. These data were in
agreement with the in vitro findings and provide a solid
basis for future clinical trials of photosensitizer carriers.
The mechanisms underlying PDT-induced apoptosis
mainly involved two signaling pathways: (1) death receptor-
mediated exogenous pathway and (2) mitochondria-
mediated endogenous pathway. It is known that activation
of the endogenous pathway rather than the exogenous
pathway is typically the main cause of PDT-induced
apoptosis [24-26]. Cytoplasmic cytochrome C (Cyc) and
apoptotic protease-activating factor 1 (Apaf-1) form a
heptameric apoptotic complex that binds to, cleaves,
and thereby activates the caspase-9 zymogen. Caspase-9
hydrolyzes and activates caspase-3/7, which reaches the
same termination point produced by the aforementioned
exogenous pathway [27-29]. The death receptor-mediated
exogenous (caspase-8) pathway ultimately activates caspase-3
to induce apoptosis. Thus, both pathways eventually in-
duce apoptosis through caspase activation.
Our experiments showed that PDTcells exhibited signifi-
cantly enhanced levels of active caspase-3 and caspase-9
proteins, which were significantly higher in nanoscale
Photosan group compared with conventional Photosan
group. These findings indicated that both Photosan-
mediated PDT induce tumor cell apoptosis via endogenous
and exogenous pathways. Relative to conventional photo-
sensitizers, nanoscale photosensitizers exhibited enhanced
photochemical efficacy and higher water solubility, and in-
creased effective drug concentrations in tumor tissues.
Thanks to these properties, the use of nanoscale enhances
the effects of photosensitizer PDT of tumor cells.
Conclusion
In summary, we performed the in vivo and in vitro
evaluation of the cytotoxic effects of Photosan-loaded
hollow silica nanoparticles on liver cancer cells. The results
showed that nanoscale photosensitizers were more effective
in inhibiting liver cancer cells compared with conventional
photosensitizer, both in vitro and in vivo.
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